-
Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) TrialB Pieske, MJ Patel, VICTORIA Study Group et al. -
Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection FractionKosmala W, Przewlocka-Kosmala M, Marwick TH et al.
-
Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human ExperienceT Simard, M Labinaz, F Zahr et al.
-
Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past?G Gulat, JE Udelson.
-
Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome?P Z Maslov, JK Kim, E Argulian et al.
-
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of AmericaDunlay SM, Givertz MM, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America.
-
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionMcMurray JJV, SD Solomon, DAPA-HF Committees and Investigators.
-
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
